Search results
Results From The WOW.Com Content Network
In September 2019, Adverum announced six-month data from the first cohort of its phase I trial. [12] The stock price dropped 50% due to investor concerns over deterioration of vision that these trial subjects suffered, as well as several reports of occular inflammation. [12] In June 2020, Laurent Fischer replaced Patterson as CEO of Adverum. [13]
The option will have a per-share exercise price equal to Adverum’s closing trading price on October 16, 2024, and will vest over four years, with 25% of the underlying shares vesting on October 16, 2025, and 1/48 th of the balance of the underlying shares vesting monthly thereafter over 36 months, subject to his continued service with Adverum ...
For premium support please call: 800-290-4726 more ways to reach us
For premium support please call: 800-290-4726 more ways to reach us
For premium support please call: 800-290-4726 more ways to reach us
The following table lists the largest biotechnology and pharmaceutical companies ranked by market capitalization in billion US dollars. The change column indicates the company's relative position in this list compared to their relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
The Dow Jones Industrial Average, an American stock index composed of 30 large companies, has changed its components 59 times since its inception, on May 26, 1896. [1] As this is a historical listing, the names here are the full legal name of the corporation on that date, with abbreviations and punctuation according to the corporation's own usage.
REDWOOD CITY, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy to preserve sight for life in highly prevalent ocular diseases, today announced topline 52-week results from the LUNA Phase 2 trial, new 4-year OPTIC long-term follow-up data and key ...